Edwards Lifesciences (NYSE: EW) revenue
Edwards Lifesciences reported revenue of $6,068m for fiscal 2025, 11.5% more than in fiscal 2024 ($5,440m). Since fiscal 2016 its revenue has grown by 104.7%, an average growth of 8.3% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $6,068m | +11.5% | $1,264m | 20.8% |
| 2024 | $5,440m | +8.6% | $1,379m | 25.3% |
| 2023 | $5,010m | +12.2% | $1,309m | 26.1% |
| 2022 | $4,464m | −14.7% | $1,498m | 33.6% |
| 2021 | $5,233m | +19.3% | $1,690m | 32.3% |
| 2020 | $4,386m | +0.9% | $897.6m | 20.5% |
| 2019 | $4,348m | +16.8% | $1,147m | 26.4% |
| 2018 | $3,723m | +8.4% | $748.2m | 20.1% |
| 2017 | $3,435m | +15.9% | $1,089m | 31.7% |
| 2016 | $2,964m | — | $751.2m | 25.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Edwards Lifesciences
- How much revenue did Edwards Lifesciences make in fiscal 2025?
- Edwards Lifesciences reported revenue of $6,068m for fiscal 2025, compared with $5,440m in fiscal 2024.
- How much has the revenue of Edwards Lifesciences grown?
- Between fiscal 2016 and fiscal 2025 it went from $2,964m to $6,068m: 104.7% more, an average growth of 8.3% a year.
- What was the best year for revenue at Edwards Lifesciences?
- Of its last 10 fiscal years, fiscal 2025, with $6,068m.
- Where do the figures for Edwards Lifesciences come from?
- From the annual report (Form 10-K) that Edwards Lifesciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Edwards Lifesciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Edwards Lifesciences: the Edwards Lifesciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.